Intercept Pharmaceuticals, Inc.

( )
ICPT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
PTLAPortola Pharmaceuticals, Inc. 0.00%17.836.5%$162.99m
HZNPHorizon Therapeutics Plc 3.40%49.566.5%$137.49m
MYOKMyoKardia, Inc. 0.72%107.501.8%$136.24m
BHCBausch Health Cos., Inc. -2.26%17.770.0%$116.19m
VRXValeant Pharmaceuticals International, Inc. -2.26%17.7714.1%$104.56m
CTLTCatalent, Inc. 0.37%78.592.3%$99.65m
AXSMAxsome Therapeutics, Inc. -2.48%80.901.9%$79.79m
UTHRUnited Therapeutics Corp. 0.32%117.5714.3%$76.94m
AMRNAmarin Corp. Plc -0.55%7.241.6%$69.65m
ICPTIntercept Pharmaceuticals, Inc. -12.19%80.5116.8%$59.84m
GWPHGW Pharmaceuticals Plc 1.33%126.926.2%$55.95m
JAZZJazz Pharmaceuticals Plc -1.14%109.592.4%$53.60m
PRGOPerrigo Co. Plc 0.00%54.336.8%$48.45m
ICLRICON plc 1.07%166.514.3%$45.86m
SAGESAGE Therapeutics, Inc. 2.53%38.948.6%$40.94m

Company Profile

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.